Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P14314
UPID:
GLU2B_HUMAN
Alternative names:
80K-H protein; Glucosidase II subunit beta; Protein kinase C substrate 60.1 kDa protein heavy chain
Alternative UPACC:
P14314; A8K318; Q96BU9; Q96D06; Q9P0W9
Background:
Glucosidase 2 subunit beta, also known as the 80K-H protein, plays a pivotal role in the maturation of glycoproteins. This enzyme acts by removing the two innermost glucose residues from the oligosaccharide precursor, a crucial step for the proper folding and function of many proteins. Additionally, it is essential for the biogenesis and plasma membrane trafficking of PKD1/Polycystin-1, a protein implicated in the primary cilia's structure and function.
Therapeutic significance:
The association of Glucosidase 2 subunit beta with Polycystic liver disease 1 highlights its potential as a therapeutic target. Understanding the role of Glucosidase 2 subunit beta could open doors to potential therapeutic strategies, especially for treating liver and possibly kidney cysts, offering hope for patients suffering from these conditions.